Research	Integrated	Name of Trial	Target Number Of	Minimum	Maximum	Target Date To	Date Agreed	Total	Date That	Total Number	Reason For Closure Of
Ethics	Integrated Research	Name of that	Patients Agreed?			Recruit Patients	to recruit	Number Of	The Trial	Of Study	Trial
Committee	Application		ratients Agreeu:	Patients	Patients	Agreed?	target	Patients	Closed To	Participants	IIIai
Reference	System			Agreed	Agreed	Agreeus	number of	Recruited	Recruitment	Recruited	
Number	Number			(Enter	(Enter		patients	At The	neeratinent	neeranea	
	- rumber			Same In	Same In		patients	Agreed			
				Both If	Both If			Target Date			
				Only One	Only One						
				Number)	Number)						
				,							
14/YH/1037	149080	MCRN3102 (KF5503/65)	Number Agreed	4	4	Date Agreed	28/11/2016	1	13/10/2016	1	Withdrawn By Sponsor
12/SW/0084	96688	LFG316 (CLFG316A2204)	Number Agreed	5	5	Date Agreed	30/11/2016	6	22/11/2016	6	Recruitment Finished
14/LO/1617	159770	GLP110933 study Type I DM Study (DRN 3266)	Number Agreed	2	2	Date Agreed	18/11/2016	2	30/11/2016	3	Recruitment Finished
15/WA/0360	184197	The TARGET All Comer Clinical Trial	Number Agreed	80	80	Date Agreed	16/12/2016	124	17/10/2016	124	Recruitment Finished
13/NW/0002		CCRN 1073 (Thoracic aortic surgery)	Number Agreed	15	15	Date Agreed	30/11/2016	21	30/11/2016	21	Recruitment Finished
15/EE/0464	183877	CRIT 4440	Number Agreed	3	3	Date Agreed	30/11/2016	2	30/11/2016	2	Recruitment Finished
15/SC/0603	114842	CCRN 2393 MAESTRO-OL	Number Agreed	1	1	Date Agreed	01/04/2017	1	01/12/2016	1	Recruitment Finished
15/WS/0121	173661	CANC - 4556	Number Agreed	4	4	Date Agreed	31/12/2016	4	09/12/2016	4	Recruitment Finished
15/SC/0311	181166	CARD 4677 VEST III PMS	Number Agreed	15	15	Date Agreed	31/01/2017	15	31/01/2017	15	Recruitment Finished
12/NW/0367	104793	PLUTO	Number Agreed	0	C	Date Agreed	31/01/2017	0	01/02/2017	0	Recruitment Finished
16/NW/0262	200188	RESP 5664	Number Agreed	1	1	Date Agreed	10/03/2017	3	10/03/2017	3	Recruitment Finished
15/SC/0242	173490	HAEM 4448	Number Agreed	1	1	Date Agreed	30/03/2021	0	13/03/2017	0	Recruitment Finished
16/LO/0055	179500	OPHT 4645	Number Agreed	8	8	Date Agreed	24/03/2017	8	30/03/2017	8	Recruitment Finished
15/SC/0409	183061	OPHT 4170 (AMD)	Number Agreed	8	8	Date Agreed	01/06/2017	8	07/04/2017	8	Recruitment Finished
13/LO/1081	132715	PROSPER: MDV3100-14	Number Agreed	6	6	Date Agreed	30/06/2017	9	23/03/2017	10	Recruitment Finished
15/LO/2045	193136	CHIL 5229 SMT C1100 in Ambulatory Boys with DMD	Number Agreed	2	2	Date Agreed	10/02/2017	2	10/02/2017	2	Recruitment Finished
		GO29438 PhaseIII?Study-									
		Atezolizumab?with?chemotherapy?in?Stage?IV?Non-									
16/SC/0161	186322	Squamous	Number Agreed	4	4	Date Agreed	31/07/2017	5	20/04/2017	5	Recruitment Finished
		A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-									
		Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus									
		Standard of Care vs. Placebo Plus Standard of Care in Subjects									
15/LO/1236	183416	with Light Chain (AL) Amyloidosis	Number Agreed	1	1	Date Agreed	31/05/2017	0	21/04/2017	0	Recruitment Finished
16/SC/0018		Study of CTX 4430 in Cystic Fibrosis Patients	Number Agreed	2	i	Date Agreed	15/05/2017		16/05/2017		Recruitment Finished
16/ES/0001		GAST 5634	Number Agreed	3	i	Date Agreed	31/08/2017	1	22/05/2017		Withdrawn By Host
10/10/0001	133033	Follow-up Study for Patients who Completed Study ALX0681-	Transcr / Igreed	†		Date Agreed	31/00/201/	_	22/03/201/	_	Tricharann By 11000
16/LO/1612	201997		Number Agreed	1	1	Date Agreed	30/11/2017	1	08/06/2017	1	Recruitment Finished
15/EM/0437	<u> </u>	COLUMBUS-AMD	Number Agreed	3	i	Date Agreed	30/06/2017	3	09/06/2017		Recruitment Finished
14/YH/1263		CRIT 3719 (Intravascular glucose monitoring system)	Number Agreed	5	i	Date Agreed	30/06/2016	3	05/04/2017		Withdrawn By Sponsor
15/LO/1441		HAEM 4790 (ALX0681-C301)	Number Agreed	3	 	Date Agreed	30/11/2017	1	08/06/2017		Recruitment Finished
16/EE/0011		Phase III Otonomy Study 104-201508	Number Agreed	1		Date Agreed	30/06/2017	2	21/07/2017		Recruitment Finished
-,,,,	12 .333	NCRN - 2890: Quizartinib (AC220) Monotherapy vs. Salvage		†		2.22.1.0.000	22,23,232,		,,,		
14/EM/0130	149751	Chemotherapy	Number Agreed	3	3	Date Agreed	31/08/2017	6	04/09/2017	6	Recruitment Finished
1, =11, 0130	1 .3.31	A 6 Month Multicentre Phase 3, Open-Label extension Safety	3.7.6.000	<u> </u>	<u> </u>		, 00, 2027		2 1, 00, 2017	Ĭ	
16/EE/0243	207331	Study of OTO-104	Number Agreed	1	1	Date Agreed	30/11/2017	5	06/09/2017	5	Recruitment Finished
-, -, -, -		CANC - 4254 - Anti-Pd-L1 Antibody (MPDL3280A) in Pediatric		†			,,,				
15/SC/0456	174561	and Young Adult	Number Agreed	2	7	Date Agreed	31/10/2018	1	29/09/2017	1	Recruitment Finished